Philadelphia University + Thomas Jefferson University
Sidney Kimmel Medical College
Department of Medicine

Jabbour, Serge

< Back

Profile

saj102

Serge A. Jabbour, DM, FACP, FACE

Contact Dr. Jabbour

Walnut Towers
211 S. Ninth Street, Suite 600
Philadelphia, PA 19107

(215) 955-1925
(215) 928-3160 fax

Medical School

St. Joseph's University, Beirut, Lebanon - 1993

Residency

Cooper Medical Center, Camden NJ

Fellowship

Thomas Jefferson University Hospital

Board Certification

Internal Medicine
Endocrinology, Diabetes & Metabolism

Hospital Appointment

Thomas Jefferson University Hospital
Methodist Hospital Division of Thomas Jefferson University Hospital

Awards & Honors

Philadelphia Magazine's Top Docs 2012, 2011

Publications

Most Recent Peer-Reviewed Publications

  1. Durability of response to dapagliflozin: a review of long-term efficacy and safety
  2. Safety and efficacy of IDegLira titrated once weekly versus twice weekly in patients with type 2 diabetes uncontrolled on oral antidiabetic drugs: DUAL VI randomized clinical trial
  3. Erratum to: Musculoskeletal manifestations of primary hyperparathyroidism (Clinical Rheumatology, (2016), 35, 12, (3081-3087), 10.1007/s10067-016-3450-3)
  4. Evaluation and management of medullary thyroid cancer
  5. Diagnosis and management of thyroid lymphoma
  6. Insulin degludec 200 Units/mL is associated with lower injection frequency and improved patient-reported outcomes compared with insulin glargine 100 Units/mL in patients with type 2 diabetes requiring high-dose insulin
  7. Musculoskeletal manifestations of primary hyperparathyroidism
  8. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial
  9. SGLT2 inhibitors
  10. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: A 24-week, multicenter, randomized, double-blind, placebo-controlled study
  11. Dapagliflozin in type 2 diabetes: Effectiveness across the spectrum of disease and over time
  12. An open label randomized phase II study of pasireotide with or without everolimus in castrate-resistant chemotherapy-naïve prostate cancer patients
  13. Dapagliflozin is effective as add-on therapy to sitagliptin with or withoutmetformin: A 24-Week, multicenter, randomized, double-blind, placebo-controlled study
  14. SGLT2 inhibitors to control glycemia in type 2 diabetes mellitus: A new approach to an old problem
  15. Comment and response to: Dapagliflozin-do we need it registered for type 2 diabetes?
  16. Collaboration designed to increase translation of diabetes research outcomes into clinical practice
  17. Targeting renal glucose reabsorption for the treatment of type 2 diabetes mellitus using the SGLT2 inhibitor Dapagliflozin
  18. Consider insulin therapy to correct perioperative hyperglycemia in both diabetic and nondiabetic patients
  19. Stop metformin before elective surgery or intravascular contrast dye study to decrease the risk of lactic acidosis
  20. Subclinical hyperthyroidism: Current concepts and scintigraphic imaging